References

T
Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol. 2021;93(11):6247-6256. doi:10.1002/jmv.27157.
Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med. 2012;51(19):2745-2747.
Takayama H, Sato T, Ikeda F, Ikeda F. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46(5):489-91.
Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54(1):87-95.
Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol. 1995;22(2):249-250.
Talal AH, Andrews P, Mcleod A, et al. Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus (HCV) management in opioid use disorder patients on methadone. Clin Infect Dis. 2019;69(2):323-331. doi:10.1093/cid/ciy899.
Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl. 2008;14(8):1081-1091.
Tang L, Parker A, Flores Y, et al. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population. J Viral Hepat. 2018;25(2):205-208. doi:10.1111/jvh.12796.
Tasillo A, Eftekhari-Yazdi G, Nolen S, et al. Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care. Obstet Gynecol. 2019;133(2):289-300. doi:10.1097/AOG.0000000000003062.
Tasillo A, Salomon JA, Trikalinos TA, Horsburgh, Jr CR, Marks SM, Linas BP. Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model. JAMA Intern Med. 2017;177(12):1755-1764. doi:10.1001/jamainternmed.2017.3941.
Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Puoti M, Rockstroh JK, Klein MB, et al., eds. Clin Infect Dis. 2008;47(11):1468-1475.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560‐1599.
Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716-726.
Terrault NA, Burton J, Ghobrial M, et al. Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors. Hepatology. 2020. doi:10.1002/hep.31551.
Terrault NA, Zeuzem S, Di Bisceglie AM, et al. HCV-TARGET study group. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5.
Terrault NA, McCaughan GW, Curry MP, et al. International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant candidates. Transplantation. 2017;101(5):945-955.
Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991.
Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study. J Infect Dis. 1998;177(6):1480-1488.
Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu. Rev. Med. 2008;59:473-485.
Thompson A, Zeuzem S, Rockstroh JK, et al. The combination of grazoprevir and elbasvir +RBV is highly effective for the treatment of GT1a-infected patients. The Liver Meeting 2015. 2015.
Top